Dyadic International Launches Public Stock Offering, Shares Plummet 11.5%
PorAinvest
jueves, 31 de julio de 2025, 12:23 am ET1 min de lectura
DYAI--
The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including product development, sales, and marketing. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission (SEC) on August 9, 2023 and declared effective by the SEC on August 25, 2023 [1].
Dyadic's stock fell 11.5% post-market on Wednesday following the announcement, reflecting investor sentiment towards the potential dilution of existing shareholders [2]. The offering signals Dyadic's need for additional funding to support its ongoing operations and growth strategies in its biotechnology business focused on precision engineered functional input proteins.
The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. Investors can obtain electronic copies of the preliminary prospectus supplement and the accompanying prospectus by visiting the SEC’s website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC.
References:
[1] https://finance.yahoo.com/news/dyadic-international-inc-announces-proposed-200200313.html
[2] https://www.stocktitan.net/news/DYAI/dyadic-international-inc-announces-proposed-public-offering-of-nhvmepesqarj.html
JUNS--
Dyadic International has initiated a public stock offering to raise funds for working capital, product development, and sales and marketing efforts. Proceeds from the offering will be used to support the company's growth and expansion. DYAI shares fell 11.5% post-market on Wednesday following the announcement.
Jupiter, Fla., July 30, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input proteins, has announced the commencement of an underwritten public offering of shares of common stock. The offering is subject to market and other conditions and is being managed by Craig-Hallum Capital Group LLC as the sole underwriter.The company intends to use the net proceeds from the offering for working capital and general corporate purposes, including product development, sales, and marketing. The securities described above are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273829) initially filed with the Securities and Exchange Commission (SEC) on August 9, 2023 and declared effective by the SEC on August 25, 2023 [1].
Dyadic's stock fell 11.5% post-market on Wednesday following the announcement, reflecting investor sentiment towards the potential dilution of existing shareholders [2]. The offering signals Dyadic's need for additional funding to support its ongoing operations and growth strategies in its biotechnology business focused on precision engineered functional input proteins.
The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. Investors can obtain electronic copies of the preliminary prospectus supplement and the accompanying prospectus by visiting the SEC’s website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC.
References:
[1] https://finance.yahoo.com/news/dyadic-international-inc-announces-proposed-200200313.html
[2] https://www.stocktitan.net/news/DYAI/dyadic-international-inc-announces-proposed-public-offering-of-nhvmepesqarj.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios